

eIF2B δ (P-6): sc-9981

BACKGROUND

The initiation of protein synthesis in eukaryotic cells is regulated by interactions between protein initiation factors and RNA molecules. The eukaryotic initiation complex eIF2B exists as a five subunit complex composed of eIF2B α , eIF2B β , eIF2B γ , eIF2B δ and eIF2B ϵ . The eIF2B complex catalyzes the exchange of GDP for GTP on the eIF2 complex, following the interaction of eIF2/GTP with the 40S ribosomal subunit. Guanine nucleotide exchange factor (GEF) activity was exhibited by the eIF2B ϵ subunit alone, but it was greater in the presence of all five eIF2B subunits. Phosphorylation of eIF2 inhibits GEF activity of eIF2B, an inhibition that requires the eIF2B α subunit.

CHROMOSOMAL LOCATION

Genetic locus: EIF2B4 (human) mapping to 2p23.3; Eif2b4 (mouse) mapping to 5 B1.

SOURCE

eIF2B δ (P-6) is a mouse monoclonal antibody raised against full length eIF2B δ of rat origin.

PRODUCT

Each vial contains 200 μ g IgG_{2b} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

eIF2B δ (P-6) is available conjugated to agarose (sc-9981 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-9981 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-9981 PE), fluorescein (sc-9981 FITC), Alexa Fluor[®] 488 (sc-9981 AF488), Alexa Fluor[®] 546 (sc-9981 AF546), Alexa Fluor[®] 594 (sc-9981 AF594) or Alexa Fluor[®] 647 (sc-9981 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor[®] 680 (sc-9981 AF680) or Alexa Fluor[®] 790 (sc-9981 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor[®] is a trademark of Molecular Probes, Inc., Oregon, USA

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

eIF2B δ (P-6) is recommended for detection of eIF2B δ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for eIF2B δ siRNA (h): sc-35276, eIF2B δ siRNA (m): sc-35277, eIF2B δ shRNA Plasmid (h): sc-35276-SH, eIF2B δ shRNA Plasmid (m): sc-35277-SH, eIF2B δ shRNA (h) Lentiviral Particles: sc-35276-V and eIF2B δ shRNA (m) Lentiviral Particles: sc-35277-V.


Molecular Weight of eIF2B δ : 60 kDa.

Positive Controls: HEL 92.1.7 cell lysate: sc-2270, WEHI-231 whole cell lysate: sc-2213 or K-562 whole cell lysate: sc-2203.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850. 4) Immunohistochemistry: use m-IgG κ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.

DATA



eIF2B δ (P-6): sc-9981. Western blot analysis of eIF2B δ expression in K-562 (A), HEL 92.1.7 (B), WEHI-231 (C), RAW 264.7 (D), M1 (E) and F9 (F) whole cell lysates.



eIF2B δ (P-6): sc-9981. Immunofluorescence staining of methanol-fixed KNRK cells showing cytoplasmic staining (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human smooth muscle tissue showing cytoplasmic staining of smooth muscle cells at high magnification. Kindly provided by The Swedish Human Protein Atlas (HPA) program (B).

SELECT PRODUCT CITATIONS

- Balachandran, S. and Barber, G.N. 2004. Defective translational control facilitates vesicular stomatitis virus oncolysis. *Cancer Cell* 5: 51-65.
- Liu, R., et al. 2011. Severity of vanishing white matter disease does not correlate with deficits in eIF2B activity or the integrity of eIF2B complexes. *Hum. Mutat.* 32: 1036-1045.
- Alves, P.K.N., et al. 2023. Leucine supplementation improves diastolic function in HfPEF by HDAC4 inhibition. *Cells* 12: 2561.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.